Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.21.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 43 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Operating Activities:      
Net loss $ (7,999) $ (3,320)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization [note 3] 64 61  
Stock-based compensation [note 6 [c] and note 6 [d]] 542 302  
Shares issued as settlement with trade vendor 23    
Changes in operating assets and liabilities:      
Amounts receivable   8  
Prepaid expenses and other assets 318 (190)  
Accounts payable 253 (675)  
Accrued liabilities other (373) (130)  
Accrued clinical liabilities 1,677 184  
Accrued compensation (952) (697)  
Lease obligation [note 7] (5) (4)  
Net cash used in operating activities (6,452) (4,461)  
Financing Activities:      
Proceeds from exercise of warrants 236    
Net cash provided by (used in) financing activities 236 (47)  
Investing Activities:      
Purchase of property and equipment   (2)  
Net cash used in investing activities   (2)  
Effect of exchange rate changes on cash   2  
Net decrease in cash, cash equivalents and restricted cash (6,216) (4,508)  
Cash, cash equivalents and restricted cash at beginning of the period 35,903 16,714  
Cash, cash equivalents and restricted cash at end of the period $ 29,687 12,206 $ 29,687
LPC [Member]      
Financing Activities:      
Financing costs relating to public offering and purchase agreement     $ (500)
LPC [Member] | Purchase Agreement [Member]      
Financing Activities:      
Proceeds financing and purchase agreement, net of issuance costs   (13)  
December 2019 Public Offering [Member]      
Financing Activities:      
Financing costs relating to public offering and purchase agreement   $ (34)